FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 275 filers reported holding FATE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.99 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $187,029 | -59.6% | 88,221 | -9.3% | 0.00% | -100.0% |
| Q2 2023 | $462,996 | -18.1% | 97,268 | -1.9% | 0.00% | 0.0% |
| Q1 2023 | $565,412 | -44.3% | 99,195 | -1.4% | 0.00% | -50.0% |
| Q4 2022 | $1,014,943 | -54.4% | 100,589 | +1.3% | 0.00% | -50.0% |
| Q3 2022 | $2,226,000 | -11.2% | 99,341 | -1.8% | 0.00% | 0.0% |
| Q2 2022 | $2,508,000 | -35.2% | 101,208 | +1.4% | 0.00% | -20.0% |
| Q1 2022 | $3,869,000 | -39.1% | 99,789 | -8.1% | 0.01% | -28.6% |
| Q4 2021 | $6,354,000 | +1.6% | 108,589 | +2.9% | 0.01% | -12.5% |
| Q3 2021 | $6,253,000 | -34.8% | 105,495 | -4.5% | 0.01% | -33.3% |
| Q2 2021 | $9,591,000 | +1.3% | 110,503 | -3.8% | 0.01% | -7.7% |
| Q1 2021 | $9,470,000 | -3.9% | 114,863 | +6.0% | 0.01% | -7.1% |
| Q4 2020 | $9,852,000 | +127.4% | 108,343 | -0.1% | 0.01% | +100.0% |
| Q3 2020 | $4,333,000 | +33.7% | 108,407 | +14.8% | 0.01% | +16.7% |
| Q2 2020 | $3,240,000 | +58.2% | 94,440 | +2.4% | 0.01% | +50.0% |
| Q1 2020 | $2,048,000 | +13.0% | 92,204 | -0.5% | 0.00% | +33.3% |
| Q4 2019 | $1,813,000 | +43.2% | 92,661 | +13.7% | 0.00% | +50.0% |
| Q3 2019 | $1,266,000 | -22.6% | 81,518 | +1.2% | 0.00% | -33.3% |
| Q2 2019 | $1,635,000 | -0.5% | 80,544 | -13.9% | 0.00% | 0.0% |
| Q1 2019 | $1,644,000 | +35.0% | 93,549 | -1.5% | 0.00% | 0.0% |
| Q4 2018 | $1,218,000 | -2.7% | 94,935 | +23.6% | 0.00% | +50.0% |
| Q3 2018 | $1,252,000 | +45.2% | 76,831 | +1.0% | 0.00% | 0.0% |
| Q2 2018 | $862,000 | +20.1% | 76,051 | +3.4% | 0.00% | 0.0% |
| Q1 2018 | $718,000 | +94.1% | 73,532 | +21.5% | 0.00% | +100.0% |
| Q4 2017 | $370,000 | +49.2% | 60,500 | -3.5% | 0.00% | 0.0% |
| Q3 2017 | $248,000 | +13.2% | 62,700 | -7.1% | 0.00% | – |
| Q2 2017 | $219,000 | – | 67,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |